- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Professor John McMurray Highlights DAPA-CKD Trial Outcomes
DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.
DAPA-CKD is the first dedicated chronic kidney disease trial of a sodium-glucose cotransporter-2 (SGLT2) inhibitor to include patients both with and without type 2 diabetes (T2D) and to specify renal outcomes as the primary endpoint. The study's positive findings build on similarly notable outcomes from the earlier DAPA-HF trial of dapagliflozin used to treat patients with heart failure with reduced ejection fraction (HFrEF) also with and without T2D.
DAPA-CKD principal investigator John McMurray, Professor of Cardiology at the University of Glasgow Institute of Cardiovascular and Medical Sciences, discussed the findings, the likes of which his nephrologist colleagues "have never seen before" with Patient Care.
